Truist Initiates Viatris (VTRS) Coverage with Buy Rating, $15 PT

Viatris Inc. (NASDAQ:VTRS) is one of the best large cap stocks to buy under $20. On October 15, Truist’s Les Sulewski initiated coverage of Viatris with a Buy rating and $15 price target. Truist acknowledges that concerns regarding legacy Viatris are still prevalent across the franchise. However, the firm maintains that there is an affirmative change in the direction of the company under its new leadership team.

This positive outlook is supported by a market-leading branded portfolio, a progressive generics foothold, and a robust pipeline with blockbuster potential. The analyst told investors that potential upside for the company could be realized through an earlier-than-anticipated return to full operations at the Indore manufacturing facility and through pipeline overdelivery.

Viatris Inc. (NASDAQ:VTRS), together with its subsidiaries, operates as a healthcare company internationally. It has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.